The FDA has warned at least 30 telehealth companies, in a batch made public March 3, 2026, over marketing claims that falsely implied their compounded semaglutide and tirzepatide products were equivalent to FDA-approved medications. That is a civil, labeling-based enforcement track. The criminal track runs through a different theory, one the Department of Justice has already proven against a telehealth prescribing platform: sham consultations, flat-fee payments to prescribers who refilled prescriptions without clinical interaction, and a pharmacy arrangement that obscured the scale of the prescribing. That theory, proven in a stimulant-prescribing case, is the architecture prosecutors are positioned to apply to compounded GLP-1 class telehealth arrangements next.
The DOJ Theory: Sham Consults and Volume Prescribing
In the Department of Justice's December 2025 indictment of a telehealth company and its affiliated medical practice, prosecutors charged that prescriptions were issued based on a short video or audio communication and limited intake documents, or no live communication at all, and that the arrangement provided few treatment options besides the drug itself. The company and practice allegedly arranged for the prescription of over 40 million stimulant pills and generated over $100 million in revenue. A related conviction of the company's founder and former clinical president supplies the third element: trial evidence showed flat-fee payments to prescribers to refill prescriptions without clinical interaction. A consultation too brief to support the prescription, payments to prescribers for issuing refills without clinical review rather than for treating patients, and few alternatives offered besides the drug are what prosecutors have targeted in telehealth prescribing arrangements, not only stimulants.
Pharmacy Steering in a Compounded GLP-1 Arrangement
A platform that routes every prescription it writes to one affiliated or preferred compounding pharmacy invites the same scrutiny applied to the pharmacy arrangement in the stimulant telehealth prosecution already described: concealing the volume or pattern of prescribing from the pharmacies and insurers that ultimately pay the claim. For a GLP-1 class telehealth arrangement, the exposure compounds because the underlying drug is itself unapproved in its compounded form, so a prescribing pattern that looks automatic rather than individualized draws both the civil labeling scrutiny the FDA has already applied and the kickback exposure under the anti-kickback statute when, for prescriptions billed to Medicare, Medicaid or another federal health care program, a pharmacy pays the platform, a marketer, or the prescriber based on prescription volume.
A telehealth platform that cannot show why a specific patient needed this prescription, as opposed to why the platform needed to write one, is building the same record DOJ used against stimulant telehealth prescribing.
From Civil Labeling Risk to Criminal Exposure
The FDA's warning letters are a civil record, not a fraud charge: they establish, in writing, that the agency considers the marketing claims false or misleading, which becomes evidence in a later civil or criminal case that a platform knew its claims were not accurate. A false claims act case can follow when those claims are billed to a federal payer. A criminal referral can follow when the pattern reaches the volume and structure DOJ has already prosecuted. The brand-side exposure, covered separately in Brand Manufacturer Lawsuits Over Compounded GLP-1 Drugs, runs on a different track, civil claims by the drug's manufacturer against compounders and telehealth sellers, and is not a substitute for a platform's own fraud exposure. Marketing claims that once leaned on the semaglutide shortage get harder to defend as the shortage closes, the shift covered in Compounded GLP-1 Marketing After the Shortage Ended.
Responding to a Civil Investigative Demand or Subpoena
A telehealth platform, a compounding pharmacy, or a prescriber that receives a civil investigative demand or a grand jury subpoena touching GLP-1 class prescribing should assume the government is testing the same three elements: consultation length and documentation, compensation structure, and pharmacy routing. What the platform produces in response either confirms individualized prescribing or confirms a volume-driven pattern.
Why Early Legal Counsel Is Critical
It is critical that telehealth platforms, compounding pharmacies, and prescribers promptly retain experienced healthcare defense counsel upon receiving a civil investigative demand, a grand jury subpoena, or an FDA warning letter touching GLP-1 class prescribing. Early legal intervention can protect the business's rights, ensure appropriate responses to government requests, avoid inadvertent admissions about consultation practices or compensation structure, preserve relevant defenses, and allow counsel to communicate with investigators on the business's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the business to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance defends telehealth platforms, compounding pharmacies, and prescribers through FDA warning letter responses, civil investigative demands, and federal fraud investigations touching GLP-1 class telehealth prescribing.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
If your telehealth platform, pharmacy, or practice has received a government inquiry involving compounded GLP-1 prescribing, contact us today for a free consultation through our Criminal Healthcare Fraud Defense practice.
